Bevacizumab can be an effective treatment for individuals with NF2 and improve different nerve functions (like hearing, tinnitus or balance problems) and the quality of life of NF2 patients. However, bevacizumab is not effective in all patients or all tumors, at the cost of moderate toxicity and considerable financial burden. Therefore, this observational study will validate an imaging biomarker method to predict bevacizumab efficacy in order to avoid adverse effects and high costs in non-responders to bevacizumab treatment. Patients will undergo standard-of-care treatment with the sole addition of a pre-treatment 89Zr-Bevacizumab PET/CT-scan. Per standard-of-care bevacizumab therapy is administered every three weeks for six months. To monitor treatment effect, follow-up is performed at 3-month intervals.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Hearing response (HR) - WRS
Timeframe: Baseline
Hearing response (HR) - WRS
Timeframe: 3 months
Hearing response (HR) - WRS
Timeframe: 6 months
Hearing response (HR) - PTA
Timeframe: Baseline
Hearing response (HR) - PTA
Timeframe: 3 months
Hearing response (HR) - PTA
Timeframe: 6 months
Radiographic response (RR) - tumor volumetry on MRI
Timeframe: Baseline
Radiographic response (RR) - tumor volumetry on MRI
Timeframe: 3 months
Radiographic response (RR) - tumor volumetry on MRI
Timeframe: 6 months
Radiographic response (RR) - ADC
Timeframe: Baseline
Radiographic response (RR) - ADC
Timeframe: 3 months
Radiographic response (RR) - ADC
Timeframe: 6 months
Radiographic response (RR) - Microbleeds
Timeframe: Baseline
Radiographic response (RR) - Microbleeds
Timeframe: 3 months
Radiographic response (RR) - Microbleeds
Timeframe: 6 months
Radiographic response (RR) - Diffusion restriction
Timeframe: Baseline
Radiographic response (RR) - Diffusion restriction
Timeframe: 3 months
Radiographic response (RR) - Diffusion restriction
Timeframe: 6 months